Sunburn, wound repair, and chronic renal failure with hemodialysis are usually accompanied by both pigmentation and itching. Proopiomelanocortin-derived a-melanocyteestimulating hormone (a-MSH) is produced in response to external stimuli, such as UV Q5 irradiation, and is involved in cutaneous pigmentation. However, it is unclear whether a-MSH is also involved in the itching. We therefore investigated whether a-MSH elicited itch-related responses in mice. We found that an intradermal injection of a-MSH induced hind-paw scratching, an itch-related response, in mice. The a-MSHeinduced scratching was inhibited by the m-opioid receptor antagonist naltrexone and the H 1 histamine receptor antagonist terfenadine. In mast cell-deficient mice, a-MSH also elicited scratching, which was inhibited by terfenadine. The immunoreactivity for L-histidine decarboxylase, a key enzyme required for the production of histamine, histamine, and the melanocortin 1 and 5 receptors were shown in not only mast cells but also keratinocytes in murine skin. In addition to the expression of L-histidine decarboxylase and melanocortin 1 and 5 receptors, the mouse keratinocyte cell lines (Pam212) also showed immunoreactivity for L-histidine decarboxylase, histamine, and melanocortin 1 and 5 receptors. The application of a-MSH induced the release of histamine from Pam212 cells. These findings indicate that a-MSH may play an important role in the itching associated with pigmented cutaneous lesions and that the histamine released from keratinocytes is involved in this a-MSHeinduced itching. (Am J Pathol 2015, -: 1e8; http://dx
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is an unpleasant sensation associated with the immediate desire to scratch, thereby making the cutaneous symptoms worse. Several skin and general conditions are associated with both pigmentation and itch. In addition, itch associated with sunburn is widely recognized to be the result of an inflammatory reaction to UV irradiation, which increases the amount of itch and erythema, after which the healing process results in later skin pigmentation. 1 Gilchrest et al 2 reported that the histamine level rises immediately after the onset of UV-induced erythema. Itch and cutaneous pigmentation also occur in association with chronic wounds and hypertrophic scars. Paul 3 noted that wound-related itch is more frequently observed in patients with severe wounds. Itch may also be caused by dry skin or serious internal diseases, such as chronic renal failure that requires hemodialysis, which is usually accompanied by cutaneous pigmentation. Taken together, it is still unclear if the underlying mechanisms of itch in these pruritic diseases involve the interaction between cutaneous pigmentation and itch.
a-Melanocyteestimulating hormone (a-MSH) is one of the neuropeptides that is generated through the cleavage of a precursor protein called proopiomelanocortin, which is produced through the production of corticotropin-releasing hormone, also known as corticotropin-releasing factor, after various stressors, such as UV irradiation.
4e7 a-MSH receptors are known as melanocortin receptors (MC1R, MC3R, MC4R, and MC5R). 4 These receptors belong to the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 G protein-coupled receptor family, and the activation of these receptors increases the production of cAMP. 8 In addition, it was also reported that a-MSH increases intracellular-free Ca 2þ concentration in human Q7 embryonic kidney cells that express these melanocortin receptors. 9 In the skin, MC1R and MC5R are mainly expressed. 10 a-MSH produced by external stimuli, such as UV irradiation, induces cutaneous pigmentation through the activation of MC1R. 4, 6, 7, 10, 11 a-MSH is also increased in plasma of patients with chronic hemodialysis 12 and in epidermal keratinocytes during cutaneous wound repair. 13 However, no previous reports indicate whether a-MSH is also involved in the itching that results from these factors.
Here, we investigated whether a-MSH elicited itch in mice. Furthermore, we performed a series of experiments to elucidate the mechanism underlying the development of a-MSHeinduced itch, focusing on the involvement of histamine, which is known to play an important role in the pathogenesis of itch.
Materials and Methods
Animals
Male ICR mice (4 to 9 weeks old), mast cell-deficient WBB6F1 W/W v (6 to 9 weeks old), and the normal littermates (WBB6F1 þ/þ , 6 to 9 weeks old) were used in this study. These mice were purchased from Japan SLC (Hamamatsu, Japan). They were housed in a room with controlled temperature (21 C to 23 C), humidity (45% to 65%), and light (7:00 AM to 7:00 PM) conditions. Food and water were available ad libitum. Procedures for animal experiments were approved by the Committee for Animal Experiments at the University of Toyama.
Cell Culture and siRNA Treatment
The murine epidermal cell line (Pam212) was cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin under standard cell culture conditions (37 C, 5% CO 2 in a humidified incubator). In a part of the experiment, siRNA-treated cells were used. siRNAs as a control, MC1R and MC5R, were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). These siRNAs were transfected with Lipofectamin RNAi MAX reagent (Life Technologies, Carlsbad, CA). The transfection was performed according to the manufacturer's protocol (Life Technologies).
Agents a-MSH was purchased from Peptide Institute, Inc. (Osaka, Japan). For in vivo experiments, a-MSH was dissolved in physiologic saline and was injected intradermally in a volume of 50 mL into the rostral skin of mice. For in vitro experiments, a-MSH was dissolved in Opti-MEM (Thermo Fisher Scientific Inc., Waltham, MA). Naltrexone hydrochloride (SigmaAldrich, St. Louis, MO) was dissolved in physiologic saline and injected subcutaneously 15 minutes before a-MSH injection. Terfenadine (Sigma-Aldrich) was suspended in 0.5% sodium carboxy methylcellulose (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and was administered 30 minutes before a-MSH injection. SQ 22,536 (Tocris Bioscience, Bristol, UK) and EGTA (Dojindo Laboratories, Kumamoto, Japan) were dissolved in dimethyl sulfoxide and diluted with Opti-MEM (final concentration dimethyl sulfoxide, 0.1%). These agents were treated 30 minutes before the application of a-MSH.
Behavioral Experiments
The day before the experiment, the hair was clipped over the rostral part of the mouse back. Before behavioral observation, the animals were placed individually in an acrylic cage composed of four compartments (13 Â 9 Â 35 cm) for at least 1 hour for acclimation. Immediately after intradermal injection, mice were put back into the same cells, and their behaviors were recorded with the use of a digital video camera (HDC-TM25; Panasonic Co., Osaka, Japan) for 1 hour with personnel kept out of the observation room. Playback of the digital recording allowed for counting of injection site scratching by the hind paw. The series of movements scratched several times for about 1 second were considered as one bout of scratching. 14 
Immunostaining
Under anesthesia with pentobarbital (80 mg/kg, intraperitoneal), mice were transcardially perfused with phosphatebuffered saline (PBS) and then 4% paraformaldehyde. The skin of the rostral back was isolated, postfixed with 4% paraformaldehyde, and immersed in 30% sucrose solution for 2 days. The tissue was embedded in Tissue-Tek O.C.T. Compound (Sakura Fineteck Co., Ltd., Tokyo, Japan) and kept at À80 C until use. The frozen samples were sectioned at 20 mm with a cryostat (Leica, Wetzlar, Germany). In the keratinocyte cell line Pam212, cells cultured on glass-bottomed dishes were washed twice with PBS and fixed with 4% paraformaldehyde. After being washed three times with PBS, the sections or cells were treated with 0.3% Triton X-100 in PBS and then with 0.25% fetal bovine serum to block nonspecific immunoglobulin binding. The sections or cells were treated with the first antibodies at a dilution of 1:100 at 4 C overnight; the antibodies used were rabbit antibodies against histidine decarboxylase (HDC; Santa Cruz Biotechnology Inc.) and histamine (Abcam, Cambridge, UK), and goat antibodies against MC1R, MC5R, and mast cell protease 5 (Santa Cruz Biotechnology Inc.). After washing, the preparations were incubated with Alexa Fluor 555-conjugated anti-goat IgG (Life Technologies) for 1 hour at room temperature. The sections and cells were rinsed in PBS after each treatment. 125  126  127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166  167  168  169  170  171  172  173  174  175  176  177  178  179  180  181  182  183  184  185  186  187   188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231  232  233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248 scanning confocal microscope (Leica Microsystems, Tokyo, Japan) or a fluorescent microscope (Olympus Co., Tokyo, Japan). After scanning, the slide glass was washed with PBS. The skin section was stained with toluidine blue and observed with the use of light microscope (Olympus Co.). For a portion of the immunostaining, we used the antibody preabsorbed with the antigen peptides as a negative control. The antigen peptides for HDC, MC1R, and MC5R were purchased from Santa Cruz Biotechnology, Inc. The preparation of the antibody preabsorbed with the antigen peptides was performed according to the manufacturer's protocol (Santa Cruz Biotechnology, Inc.).
RT-PCR
Total RNA was extracted from cultured Pam212 cells. The cell samples were lyzed with the TRIzol reagent (Invitrogen) for RNA preparation. Total RNA (0.4 mg/sample) was used for cDNA synthesis with oligo (dT) 16 primers and reverse transcriptase (Reverscript III; Wako Pure Chemical Industries Ltd.). cDNA was amplified with the use of the following primers: MC1R, 5
0 (reverse). Glyceraldehyde 3-phosphate dehydrogenase was used as a positive control. The primers used for glyceraldehyde 3-phosphate dehydrogenase were 5 0 -ACCCAGAAGACTGTGGAT-3 0 (forward) and 5 0 -TCG-TTGAGGGCAATGCCA-3 0 (reverse). The cycling conditions were 5 minutes at 94 C, 35 cycles of 30 seconds at 94 C, 30 seconds at 58 C, and 30 seconds at 72 C, and 7 minutes at 72 C. After PCR, the amplified products were analyzed by 2% agarose gel electrophoresis. after intradermal injections of a-MSH in ICR mice and effects of naltrexone. Hind-paw scratching of the injection site was counted for 1 hour after intradermal injection of a-MSH or the VH1. A: Time course of scratching after VH1 (upper panel) and a-MSH (100 nmol/L per site; lower panel) injections. B: Doseeresponse curve for the scratching effects of a-MSH and VH1. C: Naltrexone hydrochloride (1 mg/kg) or VH was injected subcutaneously 15 minutes before a-MSH (100 nmol/L per site) injection. The dotted line represents the average value of scratching bouts after intradermal injection of VH1. Data are expressed as means AE SEM. n Z 2 independent experiments (B); n Z 8 animals (C). *P < 0.05 versus VH (B, Holm-Sidák multiple comparisons; C, Student's t-test). a-MSH, a-melanocyte-stimulating hormone; VH, vehicle. 
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Proteins were extracted from cultured Pam212 cells with a lysis buffer [20 mm Tris-HCl (pH 7.5), 137 mm NaCl, 1% NP-40, 10% glycerol, 1 mm phenylmethyl sulfonyl fluoride, 10 mg/mL aprotinin, and 1 mg/mL leupeptin]. The protein lysates were denatured at 95 C
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for 5 minutes and were applied to an SDS-polyacrylamide gel for electrophoresis and transferred to nitrocellulose membranes. After blocking with 1% skim milk in PBS that contained 0.1% Tween 20, the membrane was reacted with goat polyclonal anti-HDC, anti-MC1R, anti-MC5R, and antieb-actin antibodies (dilution 1:1000 each), respectively, overnight at 4 C. After washing with PBS that contained 0.1% Tween 20, the membranes were incubated with horseradish peroxidase-labeled donkey anti-goat IgG antibody (dilution 1:1000; Bethyl Laboratories, Inc., Montgomery, TX) for 2 hours at room temperature. These membranes were then scanned with the lumino image analyzer Image Quant LAS-4000 (Fujifilm, Tokyo, Japan).
Measurement of Histamine Released from Murine Cell Line Pam212
a-MSH (200 mmol/L) was dissolved in Opti-MEM, as a reaction medium, and applied to the cells. Five and 10 minutes later, the reaction medium was collected. In the experiments that used the cells treated with siRNA, SQ 22,536, or EGTA, the reaction medium was collected 5 minutes after a-MSH application. The concentration of the released histamine was measured with the histamine enzyme immunoassay kit (Bertin Pharma, Montigny-le-Bretonneux, France) according to the manufacturer's recommendation. The protein of Pam212 cells was extracted by the application of 1% Triton X-100, and the concentration was measured by using protein assay reagent (Bio-Rad, Hercules, CA). The released histamine concentration in the reaction medium was normalized to the protein concentration of the Pam212 cells.
Statistical Analysis
All values are expressed as the means AE SEM of the respective test or control group. Statistical significance was evaluated with either Student's t-test or HolmSidák multiple comparisons. P < 0.05 was considered significant.
Results
Behavioral Effects of a-MSH
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Effects of Various Agents on the a-MSHeInduced Scratching
Subcutaneous pretreatment with 1 mg/kg selective m-opioid receptor antagonist, naltrexone hydrochloride, 15 
Effects of Mast Cell Deficiency on the a-MSHeInduced Scratching
An intradermal injection of a-MSH elicited significant scratching in both mast cell-deficient mice (WBB6F1 W/W v ) and their normal littermates (WBB6F1 þ/þ ), compared with vehicle-injected mice ( Figure 2B ). The number of scratches was almost the same between these mice. Interestingly, the administration of 30 mg/kg H 1 histamine receptor antagonist terfenadine significantly inhibited the a-MSHeinduced scratching in both mast cell-deficient mice (WBB6F1 W/W v ) and their normal littermates (WBB6F1 þ/þ ), compared with vehicle-treated mice ( Figure 2C ).
Distribution of HDC, MC1R, MC5R, and Histamine in Mouse Skin
Immunohistochemical staining showed that HDC, MC1R, and MC5R were mainly expressed in both epidermal keratinocytes and dermal cells stained with toluidine blue (Figure 3 
Release of Histamine from Pam212 Cells Stimulated with a-MSH
In the present in vivo study, an intradermal injection of a-MSH (100 nmol/50 mL Z 2 mmol/L) elicited scratching ( Figure 1A ). However, a-MSH (10 nmol/50 mL Z 200 mmol/L) led to a slight, but not significant, increase in scratching, compared with the vehicle-injected group ( Figure 1B) . Because a-MSH acts directly on the cells in vitro, a-MSH was administered at a final concentration of 200 mmol/L in these cell culture studies. Because a-MSHeinduced scratching was observed mainly during the initial 10-minute period, the release of histamine was measured for 10 minutes after a-MSH stimulation. Treatment with 200 mmol/L a-MSH significantly increased the concentration of histamine in the culture medium 5 and 10 minutes after the application of a-MSH, compared with the medium of cells treated without a-MSH ( Figure 4D ). The effect peaked after the initial 5-minute period ( Figure 4D ). 5   497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559   560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597  598  599  600  601  602  603  604  605  606  607  608  609  610  611  612  613  614  615  616  617  618  619  620 a-MSH did not elicit the release of histamine in the cells treated with MC1R or MC5R siRNA ( Figure 5 ½F5 ½F5
A and Supplemental Figure S1 ). In addition, 100 mmol/L adenylyl cyclase inhibitor SQ 22,536 17 (Supplemental Figure S2  18 ) and 1 mmol/L calcium chelator EGTA 19 also inhibited the release of histamine induced by a-MSH ( Figure 5B ).
Discussion
Intradermal injections of a-MSH into the rostral part of the skin elicited hind-paw scratching of the injection site in mice. The a-MSHeinduced scratching was inhibited by treatment with the m-opioid receptor antagonist naltrexone. It was reported that m-opioid receptor antagonists inhibit scratching induced by pruritogens 15,20e22 and dermatoses in rodents 16,23e25 and itching and scratching in humans with pruritic diseases. 26e29 However, m-opioid receptor antagonists attenuate itch-related but not pain-related behavior.
30e33
Taking into account these findings in humans and rodents, our results showing that the action of a-MSH was inhibited by m-opioid receptor antagonists are consistent with the idea that a-MSHeinduced scratching is because of pruritogenic, but not algesiogenic, stimulation of the treated skin.
In this study, we also found that a-MSHeinduced scratching was inhibited partially, but significantly, by treatment with a H 1 histamine receptor antagonist terfenadine at a dose that almost completely inhibited the histamine-induced scratching, 16 suggesting that histamine is involved in a-MSHeinduced scratching. a-MSH is involved in the pigmentation due to sunburn, 10, 11 hemodialysis, 12 and wound repair. 13 Antihistamines are effective for treating pruritus in the patients with the above-mentioned causes of pigmentation. 1,34,35 Q9 Therefore, these reports support our findings.
It is well known that histamine is mainly produced by the mast cells in skin. However, in this study, a-MSH elicited scratching in both mast cell-deficient mice and their normal littermates. Interestingly, terfenadine inhibited the a-MSHeinduced scratching in both the mast celldeficient mice and normal littermates. Taken together, these findings suggest that histamine is involved in the a-MSHeinduced scratching, and mast cells may not contribute to the release of histamine involved in this scratching.
HDC is a key enzyme in the biosynthesis of histamine.
36
In this study, we observed the immunoreactivity to HDC and histamine not only in mast cells but also keratinocytes in mouse skin. In addition, the mouse keratinocyte cell line, Pam212, also showed the immunoreactivity to HDC and histamine. Human epidermal cells and keratinocytes also express HDC. 37, 38 We also detected low (54 kDa)-and high (74 kDa)-molecular weight protein bands of HDC in the Pam212 cells; 74-kDa HDC is a precursor protein that exhibits a low enzyme activity. Furthermore, 74-kDa HDC is post-translationally cleaved to a 53-to 55-kDa species, and histamine is synthesized mainly by a 53-to 55-kDa HDC. 36 Treatment with a-MSH induced histamine release from Pam212 cells. Thus, keratinocytes may play an important role in the production of histamine, and this appears to be related to the a-MSHeinduced scratching.
In mast cells, histamine is stored in granules and is released by several types of stimuli (such as immune reactions). 36 Macrophages also express HDC and spontaneously release histamine without it being stored intracellularly (these cells do not contain histamine-storing granules). 36, 39 Because keratinocytes also do not have histamine-storing granules, the histamine would be released immediately after its biosynthesis. In this study, keratinocytes slightly produced histamine. A recent report has shown histamine induces proliferation in keratinocytes through H 4 histamine 621  622  623  624  625  626  627  628  629  630  631  632  633  634  635  636  637  638  639  640  641  642  643  644  645  646  647  648  649  650  651  652  653  654  655  656  657  658  659  660  661  662  663  664  665  666  667  668  669  670  671  672  673  674  675  676  677  678  679  680  681  682  683 receptors. 40 Thus, in a normal skin condition, histamine is involved in the proliferation in keratinocyte as one of the actions. However, overproduction of histamine induced by several stimulations, such as a-MSH (present study) and surfactant, 37 may be involved in the induction of itching. The application of a-MSH induced the release of histamine from the mouse keratinocytes cell line Pam212 in this study. Pam212 cells also expressed MC1R and MC5R receptors. The cells treated with siRNA for MC1R and MC5R showed no release of histamine after stimulation with a-MSH, suggesting that at least MC1R and MC5R are involved in a-MSHeinduced histamine release. The mechanism underlying the production of histamine after the stimulation with a-MSH is still unclear. Miyazaki et al 41 have shown that the activity of HDC was increased by N 6 ,O 2 -dibutyryl cAMP plus Ca 2þ ionophore A23187. The activation of MC1R and MC5R receptors by a-MSH increases both the production of cAMP 8 and the intracellular-free Ca 2þ concentration. 9 Here, a-MSHeinduced histamine release was inhibited by the adenylyl cyclase inhibitor, which suppressed cAMP production and a calcium chelator. Therefore, our findings suggest that increased cAMP (Supplemental Figure S2 ) and intracellular calcium levels may be involved in the production of histamine through melanocortin receptors. In the present study, the treatment with a H 1 histamine receptor antagonist did not completely inhibit the a-MSHe induced scratching. The cutaneous distribution of melanocortin receptors (MC1R, MC3R, MC4R, and MC5R) for a-MSH is not fully understood. It is known that in the mouse dorsal root ganglia, MC1R, MC3R, and MC4R, but not MC5R, are expressed, 42 suggesting that MC1R, MC3R, and MC4R are presented on primary afferents. Thus, a-MSH may act directly via primary afferents to induce itch. Recently, it was reported that there are two main types of itch-related primary afferents; H 1 histamine receptorexpressing neurons and mas-related G-coupled protein receptor A3-expressing neurons. 43 A future study should be performed to determine the distribution of melanocortin receptors in these primary afferents.
Conclusion
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